ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

By O. Cornely, Matteo Bassetti, Thierry Calandra, J. Garbino, B. Kullberg, O. Lortholary, W. Meersseman, M. Akova, M. Arendrup, S. Arikan‐Akdagli and 15 more. Clinical Microbiology and Infection, 2012

1,185 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/4ab785a6e6284ae011a8ff8c118e39e1efbf69fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. Mariana Castanheira
4. Ronald N. Jones
5. J. Turnidge
6. J. Guinea

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. Mariana Castanheira
4. J. Turnidge
5. Ronald N. Jones
6. T. Bjarnsholt
7. G. Donelli
8. J. Guinea

Citations in the corpus

• Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 (2019, background): “Caspofungin, micafungin, and anidulafungin were approved for clinical use by the US Food and Drug Administration (FDA) in 2001, 2005, and 2006, respectively, and are now recommended as firstline agents for treating IC [50, 67].”
• ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. (2015, background): “because non-removal is associated with an increased mortality and a more prolonged candidaemia [16,102,162,175–182].”